Trials / Completed
CompletedNCT05707390
A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment
A Phase 1, Multicenter, Open-label, Single-dose Study to Assess the Pharmacokinetics of Mezigdomide in Healthy Participants and Those With Mild, Moderate, and Severe Hepatic Impairment
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The aim of this study is to measure the concentration levels of mezigdomide in the blood of participants with mild, moderate, and severe hepatic impairment, and in matched healthy control participants with normal hepatic function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mezigdomide | Specified dose on specified days |
Timeline
- Start date
- 2023-02-20
- Primary completion
- 2023-09-13
- Completion
- 2023-09-13
- First posted
- 2023-01-31
- Last updated
- 2024-02-07
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05707390. Inclusion in this directory is not an endorsement.